April 12, 2024The Egyptian Journal of Radiology and Nuclear MedicineOpen Access

Role of interim positron emission tomography/computed tomography in assessment of lymphoma treatment response

View Full Paper

Ask AI

Bookmark

Authors

SBSalma M. BorgMinistry of Health and Population GSGehad A. SalehMansoura University NBNihal M. BatoutyInvestigators Research Group (United States)

Discussion

Member takes

Implication

Prospective cohort study demonstrates that interim FDG-PET/CT SUVmax predicts 24-month therapeutic response in lymphoma, highlighting its value for response-adapted therapy.

Key Points

Interim SUVmax of predominant lesions predicts both initial and 24-month therapeutic response in lymphoma, distinguishing stable or progressive disease from metabolic response.
Cutoff SUVmax of 2.75 for predominant nodal lesions achieved an AUC of 72%, separating disease progression from complete or partial Lugano response criteria classifications.
Prospective cohort assessment tracked 33 lymphoma patients over 24 months, supporting early interim PET/CT SUVmax as a reliable parameter for guiding response-adapted therapy.

Cite This Study

Borg et al. (2024) studied this question.

synapsesocial.com/papers/68e6f70ab6db64358767154c https://doi.org/10.1186/s43055-024-01247-6

View Full Paper

Ask AI

Bookmark

Implication

Prospective cohort study demonstrates that interim FDG-PET/CT SUVmax predicts 24-month therapeutic response in lymphoma, highlighting its value for response-adapted therapy.

Role of interim positron emission tomography/computed tomography in assessment of lymphoma treatment response

Discussion

Member takes

Implication

Key Points

Cite This Study

Role of interim positron emission tomography/computed tomography in assessment of lymphoma treatment response

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider